Papers, explained in our own words

169. Engineering smart liposomes to combat antimicrobial resistance: from mechanistic design to clinical translation

Gawale K, Karawadiya A, Katawale S, Sawarkar S, Omri A

Antimicrobial resistance (AMR) represents a critical global health threat, surpassing the pace of discovery and clinical development of new antimicrobial agents. Therefore, innovative therapeutic strategies are urgently needed to enhance antibiotic efficacy, overcome multidrug-resistant infections, and limit…

• antimicrobial resistance
• artificial intelligence
• biofilm eradication
• clinical translation
• nanomedicine
• precision anti-infective therapy
• smart liposomes

170. Manganese dioxide-entrapping dendrimers as a therapeutic peptide vaccine for combined tumor chemodynamic/immune therapy and tumor prevention

Xia L, Wang J, Li A, Li Y, Liu J, Shi X, Et Al.

Developing a vaccine that can both elicit robust antitumor immune responses and exert potent tumoricidal effects remains a formidable challenge. Herein, we design a functional dendrimer nanocarrier to co-deliver manganese dioxide (MnO 2 ) nanoparticles (NPs) and ovalbumin peptide antigen OVA 257-264 for synergistic…

• Chemodynamic therapy
• Dendrimers
• Immunotherapy
• Manganese dioxide nanoparticles
• Nanovaccine

171. Artificial intelligence and machine learning for magnetic nanoparticles and nanocarriers in cancer imaging, drug delivery, and magnetic control: a systematic review

Yao Y, Nafo W

We reviewed artificial intelligence and machine learning in magnetic resonance imaging-visible magnetic nanoparticles, nanocarriers, and systems for imaging, drug delivery, hyperthermia, targeting, transport, and control. Using "preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020"…

• MRI-visible nanocarriers
• artificial intelligence
• cancer drug delivery
• machine learning
• magnetic nanoparticles

172. CRISPR/Cas genome editing strategies to enhance abiotic stress tolerance in sugar crops

Liu Hb, Kumar T, Abu-Ellail Ffb, Lin Xq, Li Cj, Xu Ch, Et Al.

Sugar crops including sugarcane, sugar beets, and sweet sorghum, are fundamental for global sucrose supply and crucial feedstocks for bioethanol production and industrial bioproducts. However, yield and sucrose accumulation are significantly influenced by abiotic stresses, including drought, salinity/alkalinity…

• CRiSPR/Cas
• abiotic stress
• genome editing
• sugar beet
• sugarcane
• sweet sorghum

173. Radiolabelled Antisense miRNA Oligonucleotides for Molecular Imaging and Therapeutic Applications

Bonanno C, Romeo G

Background/Objectives: MicroRNAs (miRNAs) are small non-coding RNAs (20-24 nucleotides) that regulate post-transcriptional gene expression and are involved in key biological processes, including proliferation and apoptosis. Dysregulation of miRNA expression is associated with numerous diseases, particularly cancer…

• antisense oligonucleotides
• microRNA
• molecular imaging
• radiolabelling

174. Lipid Nanoparticle-Encapsulated mRNA Encoding CagW, a Conserved Component of the Helicobacter pylori Type IV Secretion System, Protects Mice Against H. pylori Challenge

Zhao Y, Cheng H, Zhou S, He L, Xiu C, Huang B, Et Al.

Background: Roughly one person in two carries Helicobacter pylori, a pathogen classified by the World Health Organization as a group I carcinogen, and the steady loss of antibiotic efficacy has made prophylaxis an urgent rather than an optional goal. No mRNA vaccine against this organism has yet been tested in the…

175. Beyond Targeted Delivery: The Emerging Immunomodulatory Landscape of Antibody-Oligonucleotide Conjugates

Wang Y, Wang S, Wang H

Antibody-oligonucleotide conjugates (AOCs) are usually viewed as delivery vehicles that carry nucleic-acid payloads to defined cell populations for gene silencing or gene regulation. Existing reviews concentrate on delivery systems, tumour-directed therapy and extrahepatic oligonucleotide delivery, while the…

• adjuvant
• antibody-oligonucleotide conjugate
• immunometabolic reprogramming
• innate immunity
• neutrophil

176. Metal-organic and covalent organic frameworks for precision drug delivery: a precision-by-design evidence framework for biologically accountable nanomedicine

Li X, Zhang H, Ding R, Wang F

Metal-organic frameworks and covalent organic frameworks offer a rare opportunity to design drug carriers from molecular building blocks upward. Yet high loading capacity and stimulus-responsive release alone do not constitute precision delivery. We critically synthesized evidence on MOF and COF pore-level cargo…

• biomimetic nanomedicine
• covalent organic frameworks
• metal-organic frameworks
• nanozyme
• precision drug delivery
• precision-by-design
• stimuli-responsive release
• theranostics

177. Nisin-Loaded Solid Lipid Nanoparticles (SLN-Nisin) Mitigate Treponema denticola Intracellular Infection and Restore Highly Dysregulated Host Gene Expression

Radaic A, Malone E, Lin S, Curcino Araujo Ld, Tse I, Ganther S, Et Al.

Background/Objectives: Periodontal disease is a bacterially driven chronic inflammatory condition that compromises tooth-supporting tissues. Treponema denticola is strongly associates with periodontal tissue destruction and tooth loss. Given the contribution of antibiotic overuse, the rise of multi-drug resistance…

• SLN-Nisin
• Treponema denticola
• antimicrobial peptides
• nisin
• periodontal disease
• solid lipid nanoparticles

178. Phenotype rescue through the restoration of full-length dystrophin using CRISPR/Cas9 genome editing in Duchenne muscular dystrophy patient-derived iPSCs carrying the deletion of two exons

Rovina D, Milasi S, Di Giuseppe G, Pioner Jm, Langione M, Giammarino L, Et Al.

Duchenne muscular dystrophy (DMD) is a X-linked disease affecting skeletal and cardiac muscle and is caused by mutations in the dystrophin gene (DMD). Patient-derived induced pluripotent stem cells (iPSCs) serve as reliable in vitro disease models. Their genetic correction by CRISPR/Cas9 allows the generation of…

• CRISPR/Cas9
• Duchenne muscular dystrophy
• Dystrophin
• cardiomyocytes, stromal cells, engineered heart tissue
• iPSC

179. Fucoidan-functionalized liposomal nanocarriers for targeted miR-217-5p delivery and combined antitumor treatment in pancreatic ductal adenocarcinoma

Tan C, Fang Y, Guo R, Zheng Z, He M, Yang J, Et Al.

The clinical translation of microRNA (miRNA) therapy is hindered by poor tumor specificity and inefficient delivery. In this study, we constructed a targeted nanoplatform using marine sulfated polysaccharide fucoidan (FU) to encapsulate miR-217-5p in FU-modified cationic liposomes (FU-LIP-miR) for the treatment of…

• CTNNB1
• Fucoidan
• Liposome
• PDAC
• miR-217-5p

180. An mRNA-lipid nanoparticle vaccine against H5N1 influenza virus protects lactating dairy cows from infection

Santos Jjs, Souza Ck, Zanella Gc, Goulart Db, Arruda B, Boggiatto P, Et Al.

Highly pathogenic avian influenza (HPAI) clade 2.3.4.4b H5N1 virus has recently emerged in dairy cattle in the USA, leading to mastitis and sharp reductions in milk production. The main site of H5N1 viral replication is the mammary tissue rather than the respiratory tract and viral transmission between animals is…

181. Oncolytic Virus-like Nanoparticle Targets the Golgi Apparatus via Sphingomyelin

He L, Yang L, Ren M, Wang J, Zhao W, Yang C, Et Al.

The Golgi apparatus (GA) has emerged as a promising target for cancer therapy. Commonly, therapeutics are guided to the GA by recognizing specific receptors on the GA membrane. However, the low and heterogeneous expression of these receptors often results in suboptimal targeting efficiency. Here, we present an…

• Cancer gene therapy
• Golgi apparatus targeting
• Immunogenic cell death
• Nanomedicine
• Pore-forming protein

182. Beyond Uptake in Cancer Lipid Nanomedicines: Linking Tumour Access, Intracellular Fate, and Molecular Action

Syed Hashim Sa

Clinical translation of lipid nanomedicines in oncology is limited by biological barriers and by an interpretive challenge: tumour accumulation and cellular uptake are often used as proxies for delivery even when pharmacologically competent cargo, meaning cargo capable of producing its intended molecular effect, has…

• RNA therapeutics
• cancer nanomedicine
• endosomal escape
• functional delivery
• intracellular trafficking
• lipid nanoparticles
• liposomes
• protein corona
• target engagement
• transcytosis

183. cGAS-mediated immunogenicity impairs the stability and safety of LNP-encapsulated DNA in vivo

Wang X, Liu T, Long B, Li M, Yao Y, Fu Y, Et Al.

DNA-based non-viral gene therapy offers a promising platform for titratable gain-of-function treatments, enabling multi-dosing and sustained efficacy. However, its clinical translation has been constrained by unintended immune activation. We systematically investigated the pathogenesis of DNA drug-induced toxicity in…

• LNP-DNA
• MT: Nucleic Acid Immunity
• MyD88
• TREX1
• cGAS
• gene therapy
• inflammation
• interferon
• plasmid DNA
• toxicity

184. Advances in Peptide-Functionalized Polymeric Nanocarriers for Cancer Therapy

Ommi O, Covarrubias-Zambrano O, Bossmann Sh, Kamath D

Background/Objectives: Peptide-functionalized polymeric nanocarriers are redefining targeted cancer therapy by combining the molecular specificity of peptides with the structural versatility of polymers. This review aims to highlight recent advances in peptide-functionalized polymeric nanocarrier systems designed to…

• cancer
• cell-penetrating peptides
• nanocarriers
• polymer
• targeting peptides
• therapeutic peptides
• tumor-microenvironment

185. Cell and Gene Therapy in Lung Transplantation: From Experimental Promise towards Clinical Translation

Olm F, Kortleven P, Mittendorfer M, Carlon Ms, Ceulemans Lj, Lindstedt S

Lung transplantation (LTx) remains the only definitive therapy for selected patients with end-stage lung disease, yet outcomes are limited by early ischemia-reperfusion injury (IRI) and primary graft dysfunction (PGD), and by chronic lung allograft dysfunction (CLAD) as the leading cause of late graft failure.

• Cell and gene therapy
• Ex vivo lung perfusion (EVLP)
• Ischemia-reperfusion injury (IRI)
• Lung transplantation
• Primary graft dysfunction (PGD)

186. Engineered extracellular vesicles as next-generation platforms for mRNA therapeutics delivery

Xiao Y, Tong X, Wang Z, Zhang Y, Liu S, Tian M, Et Al.

mRNA has emerged as a star molecule in pharmaceutical development, demonstrating immense potential for the diagnosis and treatment of cancer, neurological disorders, genetic diseases, and infectious diseases. It has played a particularly pivotal role in COVID-19 prevention. However, the clinical translation of mRNA…

187. Selecting Administration Routes for Therapeutic Extracellular Vesicles to Achieve Optimal Drug Delivery

Lee M, Choi Y, Yoon Sj, Kim M

Extracellular vesicles (EVs) have emerged as promising therapeutic carriers owing to their biocompatibility, low immunogenicity, and ability to transport diverse biological cargo. However, successful EV-based therapy depends not only on carrier engineering but also on selecting an administration route appropriate for…

• administration routes
• drug delivery
• extracellular vesicles

188. Cell Membrane-Coated Nanoparticles as Biomimetic Drug Delivery Systems: Design, Therapeutic Applications, and Translational Challenges

Jacob S, Varkey Nr, Rao R, Shinu P, Khanam R

Biomimetic cell membrane-coated nanoparticles (CM-NPs) have emerged as a promising class of nanocarriers that integrate the tunable physicochemical properties of engineered nanoparticles with selected biological features of naturally derived cell membranes.

• cancer therapy
• cell membrane-coated nanoparticles
• membrane surface engineering
• photodynamic therapy
• photothermal therapy
• targeted drug delivery

189. A structure-based virtual screening-driven discovery pharmaceutics platform for cancer therapeutics development: FDA 505(b)(2) repurposing of netupitant as a BMX-targeted nanomedicine using quality-by-design lipid nanoparticles and model-informed PBPK translation

Singirikonda M, Patel T, Parupathi P, Nagarajan A, Patel Js, Devarakonda L, Et Al.

Bone marrow tyrosine kinase on chromosome X (BMX) is an emerging therapeutic target implicated in prostate cancer progression, metastatic disease, and resistance to current therapies; however, no selective BMX-targeted therapy has advanced to clinical development.

• Artificial intelligence
• Bone marrow tyrosine kinase on chromosome X (BMX)
• Cancer therapeutics
• Discovery pharmaceutics
• Drug repurposing
• FDA 505(b)(2)
• Lipid nanoparticles (LNPs)
• Model-informed drug development (MIDD)
• Physiologically based pharmacokinetic (PBPK) modeling

190. In Vivo Blood Kinetics and Transcript Integrity of Three mRNA-Lipid Nanoparticle Vaccines in Humans

Kent Sj, Li S, Amarasena Th, Reynaldi A, Leeming Mg, Juno Ja, Et Al.

mRNA-lipid nanoparticle (LNP) vaccines are detectable in human blood after vaccination, but platform-specific differences in systemic persistence and transcript integrity remain poorly defined. We analyzed serial blood samples from 73 participants receiving Moderna mRNA-1273 (three formulations), Pfizer/BioNTech…

• PEG immunogenicity
• PEGylated lipid nanoparticle
• SARS-CoV-2
• bio−nano interactions
• mRNA degradation
• nanoparticle clearance and biodistribution
• vaccine pharmacokinetics

191. JAG1-siRNA-Lipid Nanoparticles Suppress Infantile Hemangioma Angiogenesis

Teng Y, Xu X, Gao J, Liu J

Background : Infantile hemangioma (IH) is the most common benign vascular tumor of infancy, and propranolol, the current first-line treatment, requires prolonged twice-daily dosing and has adverse systemic effects. Methods : Using the public GSE127487 transcriptomic dataset together with weighted gene coexpression…

• JAG1
• Notch signaling
• angiogenesis
• gene delivery
• infantile hemangioma
• lipid nanoparticle
• siRNA
• targeted nanomedicine

192. Nanoparticle-Based Drug Delivery Systems for Anticancer Therapy: Microenvironment-Driven Strategies, Advances, and Challenges

Ban M, Zhao S, Liu Z, Zhao L

Cancer remains a major global health challenge, and nanoparticle-based drug delivery systems have emerged as a promising strategy for targeted cancer therapy. However, clinical translation is still limited by an incomplete understanding of how nanoparticles navigate the tumor microenvironment (TME) throughout the…

• ATR principle
• anticancer therapy
• drug delivery
• nanoparticles
• targeting delivery